Patients and Caregivers

Denali is committed to partnering with patients to discover and develop new, effective therapies for neurodegenerative diseases.

Before a new therapy can be made available to the general public, multiple studies involving healthy volunteers and patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Currently, Denali is conducting the following clinical trials:

  • Study to Evaluate DNL201 in Subjects with Parkinson’s Disease
  • Study to Evaluate DNL747 in Subjects with Alzheimer's Disease
  • Study to Evaluate DNL747 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
  • Study to Evaluate DNL151 in Subjects with Parkinson's Disease
  • Study of Potential Treatment-Responsive Biomarkers in Hunter Syndrome

To learn more about the above studies please visit ClinicalTrials.gov

If you are interested in receiving updates from Denali about our clinical trials and research, please provide your information below.



Select all that apply to you.

For more information on Parkinson's Disease please visit EngageParkinsons.com

I am a US Resident and I agree to the Privacy Policy and Terms of Use*

Please read our Privacy Policy and Terms of Use to understand how we protect your privacy and how we may collect, use, and share information. At this time, Denali is only collecting information from residents of the United States. PLEASE DO NOT PROVIDE INFORMATION ON THE FORM BELOW IF YOU ARE NOT A UNITED STATES RESIDENT. We make no representation that the Website is appropriate or available for use outside of the United States.

* Required information

Scientific Approach